Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?

Chest. 2020 Jul;158(1):55-56. doi: 10.1016/j.chest.2020.03.040. Epub 2020 Mar 31.

Authors

Mohit Sodhi¹, Mahyar Etminan²

Affiliations

¹ Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
² Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: etminanm@mail.ubc.ca.

No abstract available

Publication types

Editorial

MeSH terms

Acetaminophen / administration & dosage
Acetaminophen / adverse effects
Antipyretics / administration & dosage
Antipyretics / adverse effects
Betacoronavirus* / drug effects
Betacoronavirus* / isolation & purification
Betacoronavirus* / physiology
COVID-19
Coronavirus Infections / diagnosis
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / physiopathology
Humans
Ibuprofen* / administration & dosage
Ibuprofen* / adverse effects
Pandemics
Patient Care Management / methods
Patient Selection
Pneumonia, Viral / diagnosis
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / physiopathology
Risk Assessment
SARS-CoV-2
Severity of Illness Index

Substances

Antipyretics
Acetaminophen
Ibuprofen